Correlation Between Inhibrx and HUTCHMED DRC
Can any of the company-specific risk be diversified away by investing in both Inhibrx and HUTCHMED DRC at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibrx and HUTCHMED DRC into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibrx and HUTCHMED DRC, you can compare the effects of market volatilities on Inhibrx and HUTCHMED DRC and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibrx with a short position of HUTCHMED DRC. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibrx and HUTCHMED DRC.
Diversification Opportunities for Inhibrx and HUTCHMED DRC
0.46 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Inhibrx and HUTCHMED is 0.46. Overlapping area represents the amount of risk that can be diversified away by holding Inhibrx and HUTCHMED DRC in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on HUTCHMED DRC and Inhibrx is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibrx are associated (or correlated) with HUTCHMED DRC. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of HUTCHMED DRC has no effect on the direction of Inhibrx i.e., Inhibrx and HUTCHMED DRC go up and down completely randomly.
Pair Corralation between Inhibrx and HUTCHMED DRC
Given the investment horizon of 90 days Inhibrx is expected to generate 0.81 times more return on investment than HUTCHMED DRC. However, Inhibrx is 1.24 times less risky than HUTCHMED DRC. It trades about -0.03 of its potential returns per unit of risk. HUTCHMED DRC is currently generating about -0.05 per unit of risk. If you would invest 1,567 in Inhibrx on September 23, 2024 and sell it today you would lose (107.00) from holding Inhibrx or give up 6.83% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Together |
Strength | Weak |
Accuracy | 100.0% |
Values | Daily Returns |
Inhibrx vs. HUTCHMED DRC
Performance |
Timeline |
Inhibrx |
HUTCHMED DRC |
Inhibrx and HUTCHMED DRC Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Inhibrx and HUTCHMED DRC
The main advantage of trading using opposite Inhibrx and HUTCHMED DRC positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibrx position performs unexpectedly, HUTCHMED DRC can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in HUTCHMED DRC will offset losses from the drop in HUTCHMED DRC's long position.Inhibrx vs. Fate Therapeutics | Inhibrx vs. Sana Biotechnology | Inhibrx vs. Caribou Biosciences | Inhibrx vs. Arcus Biosciences |
HUTCHMED DRC vs. Oric Pharmaceuticals | HUTCHMED DRC vs. Lyra Therapeutics | HUTCHMED DRC vs. Inhibrx | HUTCHMED DRC vs. ESSA Pharma |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Complementary Tools
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |